恒瑞医药：子公司降糖药获批上市，累计研发投入近1.9亿

Core Insights - The announcement highlights that the subsidiary Shandong Shengdi Pharmaceutical has received approval from the National Medical Products Administration for the launch of a new oral diabetes medication, HR20031, which is the first self-developed fixed-dose combination of three antidiabetic drugs in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin, aimed at improving blood sugar control in adult patients with type 2 diabetes who have inadequate glycemic control with metformin alone [1] - The product is available in two specifications: 5/50/750 mg and 10/100/1000 mg [1] - The total research and development investment for this product has reached approximately 189 million yuan [1] Industry Summary - Currently, there are no similar products approved for market in China, indicating a unique position for the company in the diabetes treatment market [1]